{ 128件 }
Takahashi A, Nomoto H, Onishi K, Manda S, Miya A, Kameda H, Nakamura A, Atsumi T.
A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study)
Diabete Obes Metab. in press
IF 5.8
Nomoto H, Furusawa S, Yokoyama H, Suzuki Y, Izumihara R, Oe Y, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Kurihara Y, Nakamura A, Atsumi T.
Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post-Hoc Analysis.
J Clin Endocr Metab, in press.
IF: 5.8
Asia Islet Biology and Incretin Research Association (AIBIS) 2024
トラベルグラント 千葉 幸輝先生
Sho Furusawa, Hiroshi Nomoto, Chiho Oba-Yamamoto, Jun Takeuchi, Miki Ito, Hiroyoshi Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Akinobu Nakamura, and Tatsuya Atsumi Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study) ENDOCRINE JOURNAL, in press
IF: 2.0
Aika Miya, Akinobu Nakamura, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi Frequency and Determinants of Lipid Management Target Achievement in Primary Prevention of Cardiovascular Disease in Type 2 Diabetes Diabetology International, in press.
IF: 2.2
日本糖尿病・肥満動物学会 研究賞 中村 昭伸先生
Aika Miya, Akinobu Nakamura, Hiroshi Nomoto, Hiraku Kameda, Tatsuya Atsumi Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes Endocrine Journal, in press.
IF=2.0
Iesaka H, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Abe T, Shinohara N, Atsumi T Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and
ipilimumab: A case report
Medicine, in press
IF: 1.6
Izumihara R, Nomoto H*, Kito K, Yamauchi Y, Omori K, Shibayama Y, Yanagiya S, Miya A, Kameda H, Cho KY, Nagai S, Sakuma I, Nakamura A, Atsumi T.
Switching from conventional fibrates to pemafibrate has beneficial effects on the renal function of diabetic subjects with chronic kidney disease.
Diabetes Metab J, in press.
IF: 5.9, 5-Y IF: 5.4
Sho Furusawa, Hiroshi Nomoto, Hiroki Yokoyama, Yuka Suzuki, Atsushi Tsuzuki, Kiyohiko Takahashi, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Jun Takeuchi, So Nagai, Shinji Taneda, Yoshio Kurihara, Akinobu Nakamura, Tatsuya Atsumi.
Glycemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: a multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study) Diabetes, Obesity and Metabolism, in press
IF=5.8